论文部分内容阅读
在日本大约80％的肝癌(HCC)病人伴有肝硬化,在HCC病人中继发于门静脉高压的脾亢是常见的,脾亢的特点包括脾肿大和血液循环的一系或多系细胞因素的降低,导致贫血、白细胞下降、血小板减少或任何这些因素的并发症。到目前为止,外科医生面临的问题是在处理脾亢的HCC病人时没有探索出一个被脾亢病人确定的能普遍接受的治疗方案以及恶性肿瘤病人脾切除对免疫功能的影响方面仍存有争议。
About 80% of hepatocellular carcinoma (HCC) patients in Japan are associated with cirrhosis of the liver, and hypersplenism secondary to portal hypertension is common in HCC patients. Features of hypersplenism include splenomegaly and one or more cell types of blood circulation Resulting in anemia, leukopenia, thrombocytopenia or complications of any of these factors. The problem surgeons have so far faced is that there is still controversy in the treatment of HCC patients with hypersplenism without exploring a generally accepted treatment regimen identified by patients with hypersplenism and the effects of splenectomy on immune function in patients with malignant tumors .